Affy Promises Light at End of the Tunnel After Trimming Q4 Guidance, Closing ParAllele Buy | GenomeWeb

Beset by an inability to produce enough high-resolution 500K mapping arrays to meet demand, Affymetrix will not be able to generate as much revenue in the final quarter of this year as it had previously anticipated, officials from the Bay Area firm said this week.

The announcement comes less than one month after Affy was forced to pare down its revenue expectations for Q3 and, separately, delay its acquisition of ParAllele BioScience, which closed last week (see BAN 10/05/2005).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.